STML - Stemline Therapeutics EPS misses by $0.03 revenue in-line March, 13 2020 04:48 PM Stemline Therapeutics Inc. Stemline Therapeutics (NASDAQ:STML): Q4 GAAP EPS of -$0.38 misses by $0.03.More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...